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Parvovirustype 2 (AAV-2) is a leading candidate vector for gene therapy. Cell entry starts
with attachment to a primary receptor, Heparan Sulfate Proteoglycan (HSPG) before binding to a co-receptor.
Here, cryo-electron microscopy provides direct visualization of the virus–HSPG interactions. Single particle
analysis was performed on AAV-2 complexed with a 17 kDa heparin fragment at 8.3 Å resolution. Heparin
density covers the shoulder of spikes surrounding viral 3-fold symmetry axes. Previously implicated,
positively charged residues R448/585, R451/588 and R350/487 from another subunit cluster at the center of the
heparin footprint. The footprint is much more extensive than apparent through mutagenesis, including
R347/484, K395/532 and K390/527 that are more conserved, but whose roles have been controversial. It also
includes much of a region proposed as a co-receptor site, because prior studies had not revealed heparin
interactions. Heparin density bridges over the viral 3-fold axes, indicating multi-valent attachment to
symmetry-related binding sites.
© 2008 Elsevier Inc. All rights reserved.Adeno-associated virus serotype 2 (AAV-2) was ﬁrst discovered in
tissues of children infected with adenovirus, from which its name is
derived (Laughlin et al., 1983; Salo and Mayor, 1977; Salo and Mayor,
1979). Since its discovery, AAV-2 has emerged as a leading candidate
vector for gene therapy. It was considered well-suited for develop-
ment as a vector because thewild-type virus is non-pathogenic, elicits
a low immune response, integrates itself site-speciﬁcally into
chromosome 19, infects both dividing and non-dividing cells and
has wide cell tropism (Berns and Giraud, 1995; Bueler, 1999; Chirmule
et al., 1999; Podsakoff et al., 1994; Trempe, 1996; Wu et al., 1998,
2006a, 2006b). Recombinantly engineered AAV vectors (rAAV) differ
fromwild-type in that transduction is primarily episomal, and that the
vector used is non-replicative and therefore not dependent on the
presence of helper adenovirus (Carter, 1990; Penaud-Budloo et al.,
2008). Experimental vectors have been designed to combat a variety
of diseases such as AIDS, high blood pressure, cystic ﬁbrosis, and
Parkinson's disease (Chaterjee et al.,1992; Chen et al., 1996; Flotte and
Carter, 1998; Harster et al., 1999; Inouye et al., 1997; Mandel et al.,
1997; Mochizuki et al., 2001; Phillips, 1997). However, AAV's
promiscuous cell infection may also be considered a disadvantage
and an obstacle towards the achievement of tailored cell-speciﬁcontrast transfer function; EM,
he map variance between two
se virus; HS, heparan sulfate;
n).
l rights reserved.vectors. Structural information regarding host–cell interactions could
accelerate this development.
AAV-2 is a dependovirus within the parvovirus family and is the
type species. It has an ∼4.7 kb ssDNA genome encapsulated by a T=1
icosahedral capsid built from three proteins, VP1, VP2, and VP3 in a
respective ratio of 1:1:10 (Caspar and Klug, 1962; Xie et al., 2002).
Common to all subunits is the 533 residue component, corresponding
to VP3, which was seen in the crystal structure of AAV-2, determined
to 3 Å (Xie et al., 2002). It was the infectious particles of AAV-2 that
were crystallized, containing the usual complement of VP1 and VP2,
but the unique parts of these minor capsid proteins were not observed
in the structure which was averaged according to icosahedral
symmetry (Xie et al., 2004, 2003). Relative to VP3, VP2 and VP1 are
extended by 65 and 202 residues respectively at the N-terminus. The
unique part of VP1, “VP1u” carries a phospholipase domain that is
important in transport of the viral genome from endosomes and/or
into the nucleus (Girod et al., 2002). Two conventions for residue
numbering are well-established in the literature, one counting from
the N-terminus of VP2, the other from VP1 and differing by 137 (for
AAV-2). Here, to minimize ambiguity, both will be provided in the
form VP2/VP1.
The common part of the VP1/2/3 subunit has a jelly-roll β-barrel
motif with long-loop insertions between the core β-barrel strands.
These intra-strand loops compose 60% of the structure andmost of the
distinctive surface topology. Loops from neighboring subunits inter-
digitate to form 3-fold related peaks as well as the putative receptor
binding site found along the shoulder of each peak. These loops have a
lower sequence identity (b15%) amongst different parvovirus genera
435J. O'Donnell et al. / Virology 385 (2009) 434–443and probably determine to a large extent tissue tropism (Chapman
and Rossmann, 1993). AAV-2's infection pathway is common to many
viruses.
On entering many types of cells, AAV-2 ﬁrst binds a low afﬁnity
attachment (primary) receptor, heparan sulfate proteoglycan (HSPG), to
localize on the cell surface and then requires the presence of a co-
receptor for endocytosis and infection (Summerford and Samulski,
1998). Four co-receptors have been proposed to date for AAV-2 and its
close relatives: ﬁbroblast growth factor receptor (FGFR), hepatocyte
growth factor receptor (HGFR), the 36/67 kDa Laminin receptor and
integrinsαvβ1 andαvβ5, though the latter has been questioned (Akache
et al., 2006; Asokan et al., 2006; Blackburn et al., 2006; Kashiwakura et
al., 2005; Qing et al., 1999; Qiu and Brown, 1999; Smith et al., 2004;
Summerford et al., 1999). There are alternatives to AAV-2's HPSG-
mediated cell entry, as revealed through tissue-dependent effects of
mutation at heparin-binding motifs, poor correlation of infectivity with
HSPG expression, and transduction by AAV vectors of low HSPG cells
through CD9-mediated entry (Kern et al., 2003; Kurzeder et al., 2007;
Qiu et al., 2000). Other serotypes, AAV-1, -4, -5, and -6, bind to sialic acid
with different speciﬁcities for its various forms (Kaludov et al., 2001;
Walters et al., 2001; Wu et al., 2006c). Thus, while cell entry is more
complicated than once presumed, the consensus is that HSPG-binding
plays an important, often dominant, role for at least AAV-2 and AAV-3
(Kurzeder et al., 2007).
HSPG is found on the surface of many cells. It is comprised of an
integral membrane protein with an attached heparan sulfate (HS). HS,
like heparin, is a linear polysaccharide glucuronic/iduronic acid and
glucosamine residues. The N- and O-linked sulfates of such hepar-
inoids impart a negative charge which is implicated in their biological
interactions with growth factors, chemokines, proteases, and patho-
gens (Conrad, 1998). HS differs from heparin in a higher diversity of
disaccharides, lower levels of sulfonation and greater ubiquity, but
heparin which is more speciﬁc to mast cells is a close analog that is
prepared for pharmaceutical use and is commonly used as a structural
and functional analog (Conrad, 1998). Examples of viruses that use HS
for cellular attachment include Foot and Mouth disease virus (FMDV),
Herpes Simples Virus (HSV-1), human immunodeﬁciency virus (HIV-
1), respiratory syncytial virus, Dengue virus, and several alphaviruses
(Capila and Linhardt, 2002; Chen et al., 1997; Conrad, 1998; Jackson et
al., 1996; Krusat and Streckert, 1997; Patel et al., 1993; WuDunn and
Spear, 1989; Zhang et al., 2005). Atomic structures of Heparin–protein
complexes have shown that interactions are often dominated by
multiple ionic pairs between arginines and heparin's sulfate groups
while polar interactions with sugar hydroxyls are also common (Carﬁ
et al., 2001; Dementiev et al., 2004; DiGabriele et al., 1998; Faham et
al., 1996; Lietha et al., 2001; Mulloy and Linhardt, 2001). Beyond this,
there is little conservation of a binding motif between different HS-
binding proteins so recognition of binding sequences is difﬁcult
(Hileman et al., 1998). In the report of the crystal structure of FMDV
subtype 01, complexed with heparin, it was suggested that a single
heparin fragment could bridge between multiple receptor sites on the
symmetrical virus capsid (Fry et al., 1999). It was proposed that weak
binding interactions of individual sites could be combined to achieve
strong binding in sum.
The crystal structure of AAV-2, and calculation of the surface
electrostatic potential suggested that the HS binding site might be a
patch of strong positive charge on the shoulder of surface protrusions
where 4 arginines and a lysine come together (Xie et al., 2002).
Subsequently, three independent mutagenesis studies tested this
postulate, and all concluded that basic residues on the capsid surface
were crucial for HSPG binding and cell infection (Kern et al., 2003;
Lochrie et al., 2006; Opie et al., 2003). There is consensus that a cluster
of positively charged residues on the side of each 3-fold peak,
speciﬁcally R448/585, R451/588 and R350/487 are involved in heparin
binding. Unresolved issues include the lack of conservation of, R451/588
and R350/487 among heparin-binding serotypes, and differing experi-mental characterizations of mutations at more conserved sites,
including R347/484, R350/487 and K395/532.
Reported here are cryo-EM reconstructions of AAV-2 with and
without a 17 kDa receptor analog fragment at resolutions of 8.3 Å and
7.8 Å respectively. Difference map analysis shows the strongest peak as
an elongated ellipsoidal shape laying tangential to capsid surface
directly over the basic residues R448/585 and R451/588 and extending
toward R347/484, R350/487 and K395/532, in fact enclosing a footprint much
larger than previously appreciated. At lower contour levels, difference
density extends between 3-fold and also 2-fold related binding sites,
indicating a single polysaccharide receptor bridges between multiple
sites which together presumably achieve tighter attachment.
Results and discussion
Quality of the electron microscopic reconstructions
AAV-2 complexed with a 17 kDa receptor analog fragment,
together with a native control, has been visualized through cryo-EM
reconstruction (Figs. 1A, C) at resolutions of 8.3 Å and 7.8 Å
respectively (Fig. 2) that are among the highest that have been
obtained for any parvovirus (Kaufmann et al., 2008). The reconstruc-
tion of the native virus was built from 7491 particle images.
The agreement between the EM reconstruction of the native virus
and the crystallographic structure is excellent, even though perfect
agreement should not be expected at 8 Å resolution. All surface
features characteristic of AAV-2 are apparent, including conspicuous
3-fold related peaks, a 2-fold dimple and an empty 5-fold channel. The
overall consistency is remarkably good, and improved relative to the
earlier EM visualizations of AAV-2 particles at ca. 10 Å resolution
(Kronenberg et al., 2005). Several hairpin loops, comprised of just two
antiparallel backbone chains are clearly visible on the surface, such as
the EF loop between β-strands E and F, ﬁve symmetry-equivalent
copies of which form distinctive outer surface features surrounding
the 5-fold axis (Fig. 2).
Interpretation was restricted to map features exceeding 3 or 4 error
units. This threshold appears to be robust from several perspectives:
(1) the mock difference map (odd–even images) gives highest peaks
in general positions of ±3 e.u. (noting that symmetry axes can have
higher noise). (2) The native EM map, contoured at 3.8 e.u. gives good
correspondence to the crystallographic structure — at 4.4 e.u. some
parts are outside the density, while at 1.8 e.u. all is enclosed within a
possibly over-generous envelope. (3) If a single 17 kDa fragment were
bound at each of 60 symmetrical sites, the appropriate volume would
be enclosed by an isocontour at 2.5 e.u., 4.5 e.u. if each heparin bridges
between two binding sites. Thus, three different criteria suggest that the
transition from noise to real features occurs between +2.5 and +4.5 e.u.
The reconstruction of the HS-complex was built from 5950
individual virion images (Figs. 1B, D). Overall, there is a good
agreement with the native reconstruction. Extra density in the map
of the complex covers the entire 3-fold area. The differences between
heparin-complex and native are most apparent in the difference map
which is interpreted below, but all of the signiﬁcant features could
also be seen in the map of the complex (Fig. 1).
Visualization of the bound heparin receptor analog
In the heparin-native difference map, the strongest density at
+6.9 e.u. is located just off the viral surface near a concentration of
6 positively charged residues. The closest is R448/585, about 5 Å away
from the highest density (Table 1 and Figs. 3 and 4). Strong density N
+6 e.u. wraps around neighboring side chains, R448/585 and R451/588
(Table 1), which are on the inner shoulder of each peak surrounding
the 3-fold axes. Density at +5.2 e.u extends from each of the shoulders,
connecting over and around the 3-fold axes, bridging the 28 Å wide
valley between 3-fold-related peak shoulders. If the contour level is
Fig. 1. 3-D electron microscope reconstructions of native (A, C) and heparin-complexed AAV-2 (B, D) at 7.8 and 8.3 Å resolution respectively. Panels A and B show stereo pairs of the
outer surface, while C and D show cut-aways to reveal the inner surface, all viewed in the same orientation down a 2-fold axis of symmetry. Maps were spherically masked (at 80 and
160 Å) for clarity. (Note that while the particles imaged contained DNA, generally it was not seen above noise levels at these resolutions, because its structure was disordered.) In
panels A and B, maps are colored according to distance from the center (from green to yellow to brown). The arrow in panel B points to the general vicinity of the bound receptor. At
this contour level (4.4 e.u.), relative to the native particle in panel A, density is added to the lower surface of the 3-fold peak, and connecting density can be seen extending to a
neighboring peak. In panels C and D, coloring is by strength of the density, from weakest (2.5 e.u., red) to strongest (25 e.u., blue). Some of the icosahedral symmetry axes are
annotated in panel D. The differences between the complexed (D) and native (C) are subtle, and will be best visualized in difference maps in later ﬁgures. However, the map of the
complex has extra density between the 3-fold proximal surface peaks. The point to be emphasized from panels C and D are that the addition of the heparin makes little difference to
the capsid protein structure.
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from the bottom (120 Å from the virus center) on the 3-fold to a
surface at ∼150 Å from the virus center. The entire 3-fold side of each
of the peaks is covered, except for themost exposed residues, P314/451–
T319/456, that protrude ∼10 Å above the heparin at the distal end of the
peak, ∼160 Å from the virus center. The three peaks surrounding each
3-fold axis thereby become interconnected with heparin density.
Connections between different 3-fold regions are also present,
extending over the 2-fold axes, but at a lower density level (+2.5
e.u.) where the signiﬁcance is borderline.
A crude estimate of the heparin occupancy was obtained by
comparing the highest peaks in the complex map in the heparin and
capsid protein regions. The heparin density is about 1/3 of the height,providing an estimate of the heparin occupancy that is a lower bound
to the degree that the heparin is more disordered and of weaker
density than the capsid protein. The fragment size used in this study is
∼17 kDa or ∼70 monosaccharide units. It was larger than the
oligosaccharides used in prior preliminary experiments, and not
only easier to visualize by EM, but it better represents physiological
interactions. However, with a long polymer, the heparin likely exists as
a population of many possible conﬁgurations. Its density will be
smeared where different polysaccharide conformations are averaged
by the icosahedral symmetry applied in 3-D reconstruction.
How long is the heparin polymer? Extrapolating from the structure
of the fragment bound in the crystallographic study of FMDV, the
17 kDa fragment used here could be as long as ∼285 Å. In an extended
Fig. 2. Assessment of map quality. (A) Fourier shell correlation (FSC) comparing the signal from two halves of the image set as a function of resolution. The correlation for the virus
alone is shown in solid line and that of the heparin complex dashed. Resolutions are estimated from the points at which the correlation coefﬁcients drop below 0.5. (B) Example
region of the 7.8 Å resolution native reconstruction rendered at ∼8 e.u and overlaid on the crystallographic structure. The view is inwards, parallel to a 5-fold axis, around which 3
copies of the HI loop can be seen on the right, with two copies of the EF loop (top left and bottom). The reconstruction allows features of the virus to be resolved at the level of surface
loops.
437J. O'Donnell et al. / Virology 385 (2009) 434–443conﬁguration this corresponds to 1/3 of the virus' circumference. At
this length, a single heparin could bridge between multiple trimers.
There may be many ways of winding between 3-fold peaks and
connecting between adjacent capsid binding sites. 60-fold averaging
over the different conﬁgurations will lead to diffuse heparin density.
Furthermore, some paths of the polymer will be mutually exclusive.
Thus, once two neighboring sites have been connected directly over
the 3-fold, the same binding conﬁguration is not available for the third
equivalent site. In summary, an occupancy of less than one representsTable 1
Basic amino acids proximal to the highest sub-peaks in the heparin-native difference map
Peak height Position Distances (Å)
Chain A
R347/484 Nη R350/487 Nη
6.9 e.u. (2.5, 25.0, 132.8) 13.4 7.3
6.3 e.u. (2.3, 34.8, 135.0) (13.4) (13.2)
6.2 e.u. (−4.6, 37.6, 133.2) 13.2 (14.7)
Aligned residues
in serotypes
1/3/4/5/6/7/8/9 RRKRRRRR RRGGRRRR
Coordinates are given in a 222a reference frame in which icosahedral 2-folds are aligned w
measured to the point of maximal density, and do not account for the size of a bound hepa
contact the difference density envelope that would encompass all three sub-peaks. Distances
chain.a combination of steric exclusion, the averaging of statically
disordered conformations and dynamic ﬂexibility of the polymer
chain, all of which lower the heparin density andmake it more diffuse.
Each of the 3-fold symmetric parts of the heparin density can
be modeled with a nonasaccharide. The sample heterogeneity and
structural disorder discussed above, together with the modest
resolution mean that the density lacks the distinctive features
required to discern polysaccharide sequence, chain direction or
exact conformation. Thus, only a crude model was warranted, builtChain G
K390/527 Nζ K395/532 Nζ R448/585 Nη R451/588 Nη
8.9 8.8 4.7 6.9
(15.6) (17.9) 4.5 4.3
(18.5) (19.5) 7.5 6.9
KKGKKKKK KKSNKRRR SSSSSAQS TTNTTTTA
ith the principal axes. Chain “G” is a 3-fold equivalent of protomer “A”. Distances are
rin molecule. If the contour level were dropped to 3 e.u., all tabulated residues would
are given in parentheses if access to the density peak would be occluded by another side
438 J. O'Donnell et al. / Virology 385 (2009) 434–443by connecting rigidly ﬁt monosaccharide units from RSCB entry 1SR5
using the program Coot (Emsley and Cowtan, 2004). Two of the three
symmetry equivalent 9-mers can be connected through each 3-fold
(Fig. 4B), so the density may represent the average of possible paths of
18 of the ∼70 monosaccharide units in each sample molecule. Such a
conﬁguration allows the observable part of each heparin to wind
through the strongest difference density, that is on the positively
charged sides of two 3-fold proximal peaks (Fig. 3D and Fig. 4A). It is
the regions where the heparin is mostly tightly bound that give the
strongest density. The rest of the heparin is too disordered to
visualize, but there are hints with density at about noise level, that
the chains can also bridge between the 3-fold regions over the 2-fold
axes.
Search for possible receptor-induced conformational changes
The differencemap has been examined systematically for evidence
of heparin-induced conformational change in the capsid (Fig. 3).
Protein conformational change should be apparent with adjacent
negative and positive density in the difference map indicating the
unbound and bound conﬁgurations. The most negative difference
density is on the inside surface of the capsid where there are several
peaks of ∼−6 e.u. all ∼83 Å from the virus center. Both complex and
nativemaps have strong negative peaks, up to∼−20 e.u. that are about
2/3 of the strength of the maximal capsid protein positive density. The
spherical shape of capsids can lead to superposition of truncation
ripples and to larger-than-usual series termination effects on the
inside of the capsid. These peaks correspond to modest differences
between densities that are strongly negative in both complex and
native, and therefore do not represent conformational change. The
only other negative feature (−4.0 e.u.) in the difference map
commensurate with the estimated noise is also in a location that is
negative in both complex and native (Fig. 3C). It also sits 11 Å off the
surface beyond molecular rationalization.
The positive peaks in the difference map can similarly be analyzed.
After the peak near residues R448/585 and R451/588, there is difference
density on the 5-fold that is almost as strong, ∼108 Å from the virus
center. The ﬁlling of the 5-fold pore, 21 Å wide at this point would be
intriguing, but the expected noise on a 5-fold axis is sqrt(5)-fold
higher, so this feature is not experimentally signiﬁcant. The next
strongest peak (3.5 e.u.) is at the noise level in a surface pocket
between K528/665 and C224/361. The map of the complex covers the
structure more generously than that of the native, resulting in a small
peak in the center of the pocket that is not experimentally signiﬁcant.
What should not be lost in this detailed discussion is that there is
no evidence for large scale receptor-induced conformational changes.
It is only the density near the 3-fold that rises clearly above the noise.
There are several other peaks at about the noise level, but there are no
paired regions of positive and negative density that would be
indicative of conformational change. Furthermore, there is noFig. 3. Differences between cryo-EM reconstructions of the heparin-complex and native AAV
surface) are the positive (red) and negative (green) regions of the differencemap. The icosahe
divided into 60 equivalent triangular areas. The strongest positive difference densities surro
(translucent) and ±5 e.u. (solid surface) shows that these peaks are the most massive. (B) The
related capsid proteins are shown in Cα trace. Positive density is red, negative is blue, both co
capsid surface, 83 Å from the virus center at the boundary between protein and DNA. The next
axis. These are comparable with the experimental noise level of ∼3 e.u. (see text) and lie 11
proximal heparin peaks described in panel A. The next strongest positive peaks are on the 5-fo
so these peaks are not experimentally signiﬁcant. (C) Sections through the cryo-EM reconstr
are annotated. The grey-scale runs from dark (negative density) towhite (positive). The green
At this location, 11 Å from the viral surface, the density in both native and complex is nega
density, highlighted with a red arrow in panels A and C, is clearly more positive than that
prominent difference peak. The view is similar to the boxed region in panel A, with a 3-fold a
EM reconstruction of the native virus contoured at 3.1 e.u. and colored according to the el
carbons). The red net shows the EM difference density contoured at +4.7 e.u., with the stron
valley between spikes from the bottom of the valley at 120 Å to a “height” from the viral cent
strongest density of the heparin (which carries negatively charged sulfates) lies above a paconnection of these peaks to the site of heparin attachment near the
3-fold.
Even though large conformational changes are not observed, there
may be side chain rearrangements and small heparin-induced
backbone adjustments which would only be seen at resolutions
better than 8 Å. It is also possible that subtle changes are masked by
the partial heparin occupancy leading to a mixture of states in the
complex. It is also possible that conformational change could depend
upon asymmetry between a bound site and unoccupied neighbors,
which is not seen in the current multi-ligand complex, but, to the
authors, this seems implausible in the absence of any observed
conformational changes. In summary, with several caveats, this study
cannot exclude the possibility that there are subtle changes of small
magnitude, but it does rule out large receptor-induced conformational
changes that would have been apparent in maps of such high quality.
Capsid–receptor interactions
Intriguingly, the contact residues for the most tightly bound part
of the heparin are R448/R585, R451/588 which are not conserved among
AAV serotypes, even those that are closely related, such as AAV-3 and
AAV-6, human serotypes that are known to bind heparin and are 89%
and 85% identical in capsid sequence respectively (Negishi et al.,
2004; Rutledge et al., 1998; Wu et al., 2006a) (Table 1). In the other
serotypes, they are replaced, for the most part, with polar residues,
Ser, Thr, Gln or Asn that are also commonly part of heparin-binding
regions (Conrad, 1998), but unlikely to form associations that are as
strong. The non-conserved R448/R585, R451/588 form part of a conti-
guous positively charged surface with R347/484, R350/487, and are close
to K395/532 (Xie et al., 2002) (Fig. 4A), but there has not been
consensus in prior studies of the importance of these residues. There
are many plausible reasons for apparent discrepancies including
possible differences between cell entry via heparan sulfate attach-
ment and physical measures of the binding to the analog, heparin.
Much can be learned by integrating the current complex structure
with three prior studies inwhich the effects of mutatingmany of these
residues upon heparin bindingwere assayed (Kern et al., 2003; Lochrie
et al., 2006; Opie et al., 2003). R448/585 and R451/588, which had strong
impact in all three studies, are in the center of the observed heparin-
binding site. R350/487 and R347/484 were found to be important in the
study of Kern et al. (2003), but less so in the studies of Opie et al. (2003)
and Lochrie et al. (2006). The current EM structure shows that R350/487
makes contact with the heparin density just below R448/585 while R347/
484 is only slightly further removed, and still in the ﬁrst shell of heparin
neighbors to the side of R451/588. There has been greater discrepancy in
the mutational data for K395/532, and K390/527 leading to different
conclusions about their importance. The EM structure shows that both
are in contact with the edge of the heparin, supporting the earlier, not
later,mutational data. On the other hand, R347/484, studied byKern et al.
(2003) is buried four amino acids below, indicating that anyeffect upon-2. (A) Superimposed on the EM reconstruction of the native particle (gray translucent
dral symmetry axes are shownwith arrows (the view is down a 5-fold) and the surface is
unds each 3-fold axes, rising to 6.9 e.u. Contouring of the difference density at ±4 e.u.
difference density is shown in a cross-sectionwith a 5-fold axis vertical. Five symmetry-
ntoured at ±3, ±4, and ±5 e.u. The strongest negative peaks (∼−6.0 e.u.) are on the inner
strongest negative density forms a ring of peaks at −3 to −4 e.u. surrounding each 5-fold
from the viral surface. The strong positive density at the top left and right are the 3-fold
ld axes of symmetry where noise levels are expected to be 2.2× that of general positions,
uctions ∼2.45 Å from a plane containing multiple 2-, 3- and 5-fold axes, some of which
arrows point to the regionwhere negative peaks (−3 to −4 e.u.) surround the 5-fold axis.
tive, suggestive of experimental error or solvent differences. By contrast, the stronger
in the native and is the site where heparin binds. (D) Stereoscopic image of the most
xis rotated ∼17° clockwise from vertical and ∼32° forwards. The surface shows the cryo-
ectrostatic potential of the underlying crystallographic structure (ball-and-stick, green
gest regions (∼6.5 e.u.) highlighted using magenta spheres. The density ﬁlls most of the
er of ∼150 Å, leaving the most distal residues of the viral surface exposed. Note that the
rt of the valley that is strongly positively charged (blue).
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mutant studied by Lochrie et al. (2006) is slightly removed
from the heparin, but sits immediately below K390/527, so a
collateral effect upon heparin-binding is plausible. The measured
effects upon heparin-binding of several multi-site mutants
(Lochrie et al., 2006) is more difﬁcult to rationalize unless
there are more substantial collateral effects through which
buried residues have impact, or unless the modest changes in
binding are within experimental error.In summary, consensus emerged from mutagenesis studies
that R448/585, R451/588 and R347/484 are critical in AAV-2/HS
interactions. There has been little agreement on three other
basic residues in the area: R350/487, K395/532 and K390/527 whose
contact may be less intimate, but, as now seen, also fall within
the binding footprint. The current EM structure shows, for the
ﬁrst time, the full extent of the footprint. The structure
arbiters the inconsistencies between the mutagenesis studies,
and suggests that some of the assays reveal the strongest
440 J. O'Donnell et al. / Virology 385 (2009) 434–443interactions, while others remain undetected. This is relevant to
the following point.
The mutagenesis data have also been used to infer co-receptor
interactions in cases where mutation affects infectivity or transduc-
tion, but not heparin binding (Lochrie et al., 2006). Details of the
interpretation need revision in light of the structure reported here.The heparin binding footprint is much larger than implicated by
Lochrie et al., comprising a contiguous area of 36 amino acids (Table 2).
This footprint is consistent with the prior studies in that it encloses all
surface residues positively implicated in at least one of the mutage-
nesis studies. Within this area, however, are many additional residues
whose interactions with heparin were not detected by the prior
Table 2
Amino acids at the AAV-2 heparin interface
Direct Neighbor Direct Neighbor Direct Neighbor
Q320/457 K390/527 E437/574 Q438/575
R347/484 D391/528 T444/581
R350/487 D392/529 N445/582
A356/493 E393/530 L446/583
D357/494 K395/532 R448/585
N359/496 F396/533 G449/586
N360/497 S361/498 N450/587
T366/503 W365/502 R451/588
K370/507 Q452/589
H372/509 A454/591
G375/512 T455/592 A456/593
D377/514 D457/594
N459/596
K569/706
Direct contacts with the density (contoured at 4.7 e.u.) are made by 23 amino acids.
Another 13 have side chains with unobstructed access to the density through a short
gap that might be ﬁlled with solvent or disordered parts of the heparin.
441J. O'Donnell et al. / Virology 385 (2009) 434–443methods. Of the 36 amino acids in the footprint, 19 have previously
been mutated with 6 having detectable impact in at least one of the
studies. Those successfully identiﬁed were core interactions with
positively charged residues. Remaining undetected were contribu-
tions from neighboring polar side chains that are also expected to
contribute (Conrad, 1998). The apparent lack of heparin interaction
combined with impact upon transduction led one study to conclude
that a “dead zone” region on the plateau where such residues were
concentrated was the likely site of co-receptor binding (Lochrie et al.,
2006). However, the footprint revealed in the current work includes
10 of the 17 amino acids assigned to this site. This does not eliminate
the possibility that the plateau is involved with co-receptor binding,
but it undercuts a principal argument. The issue remains open
pending more deﬁnitive evidence. Given the laboratory-dependent
variation in assaying several mutants, it is reasonable to question
whether some heparin interactions have been harder to detect than
effects upon transduction. Alternatively, it is possible that some
mutations within the footprint might have an indirect effect upon
transduction that is greater than a direct affect upon heparin binding,
if HSPG still binds, but in a conformation that is not so favorable for
ternary interactions between virus, HSPG and co-receptor needed for
cell entry. In fact, this is only one of many possible explanations, but
speculation should be limited until it is understood whether the
variation in reported mutant phenotypes reﬂects something more
signiﬁcant than experimental errors and sensitivity.
In the current work, more questions are re-opened than answered.
However, visualization of the full footprint has taken us beyond the
prior mutagenic studies, resolving some of the past discrepancies. The
broad extent of the footprint has provided a foundation for under-
standing how serotypes such as AAV-3 might bind HSPG, albeit withFig. 4. Molecular interpretation of EM results (stereoscopic images). (A) The interactions of
one of the peaks surrounding a 3-fold (left arrow). In this stereodiagram, the cut-away transl
3.1 e.u. and colored according to the electrostatic potential from red (most negative) to blue
and-stick). Behind the translucent surface can be seen a chicken-wire representation of the di
strongest regions highlighted by magenta spheres. The heparin density coincides with a posi
positively charged amine and guanidinium groups (blue nitrogens) of Lys390/527 and Arg350
together with Arg347/484 of subunit A, also in the vicinity, have been implicated in heparin-bin
al., 2002). (B) The difference density, contoured in red at 4.9 e.u. is commensurate in size with
arrow). (Heparin is a heterogenousmixture— themodel is not intended to represent accurate
The green translucent surface shows the cryo-EM reconstruction of native AAV-2 at 7.8 Å reso
heparin density, contoured at 4.7 e.u., is overlaid on the atomic structure which is colored acc
studies. Side chains are colored with positively changed atoms blue, negatively charged ato
combining the results of three studies (Kern et al., 2003; Lochrie et al., 2006; Opie et al., 2003)
shaded for the strongest effects. Residues that did not appear to affect heparin binding are c
levels or infectivity. The heparin footprint has at its center the three residues with stronge
residues for which consistent mutagenesis results have not been obtained. The footprint con
The gold-colored residues were previously hypothesized to affect transduction through a sec
several are within the heparin footprint.different afﬁnity, even though residues previously implicated in AAV-
2/heparin interactions are not conserved. The size of the footprint
highlights the potential importance of ternary virus interactions
involving both primary and secondary receptors. Finally, connecting
heparin density between symmetry-related binding sites indicates
how higher afﬁnity multi-valent binding can be achieved.
Materials and methods
Virus was propagated in HeLa cells, and puriﬁed by cesium
chloride density gradient ultracentrifugation as previously described
(Xie et al., 2004). Virus was dialyzed out of the 3 M CsCl salt and into a
low salt buffer (125 mM NaCl, 10 mM Tris, and 1 mM MgCl2 pH 7.5)
using 50 μl custom-built microdialysis cells. Quantifoil R2/1 grids were
used to prepare vitriﬁed, thin layer samples. The grids were pre-
coated with carbon, but an additional continuous carbon layer was
applied to enhance contrast for particle identiﬁcation and strengthen
the Thon rings of the power spectrum used to determine the
appropriate contrast transfer function (CTF) correction. The grids
were glow discharged immediately prior to sample application. For
the native sample, 4 μl of virus solution at 1.1 mg/ml was applied to
grids, blotted to remove excess, and plunged into liquid ethane for
vitriﬁcation. Grids were transferred to liquid nitrogen for long term
storage. Attempts to pre-incubate virus with heparin for as little as an
hour, resulted in severe aggregation, evenwith10-fold molar excess of
heparin relative to capsid protein (600-fold excess relative to virus
particles). The aggregates, containing many virus particles cross-
linked by heparin, were not suitable for the preparation of thin
specimens needed for high resolution EM. Thus, samples were
prepared using dilute AAV-2 that had been pre-adsorbed onto EM
grids, such that heparin polymers were complexed with individual
viruses that were of ﬁxed location. Note that the procedure is different
from the chemical ﬁxation used in other types of microscopy, in that
the adsorption involves weak, non-speciﬁc interactions that are
neither expected to induce conformational distortions or to inhibit
changes induced by ligands. However, the procedure will reduce
slightly the occupancy of the receptor, because a handful of the 60
symmetry-equivalent binding sites will be occluded where the virus
contacts the EM grid. Heparin was purchased from Sigma Aldrich, Inc.
(sodium salt, ∼17 kDa fragment, catalog # H3393) and solubilized in
distilled water at 10 mg/ml. 4 μl of virus at 1.1 mg/ml was added to the
grid, as before. After blotting off excess, 4 μl of receptor solution at
2.5 mg/ml was added to achieve a 10-fold molar excess relative to the
capsid protein that had been applied. Thirty seconds later, the grids
were again blotted and ﬂash frozen. The grids were transferred to a
pre-cooled Gatan cryotransfer holder and inserted into a Philips CM-
300 FEG electron microscope. Images were collected under low dose
conditions (20e¯/Å2) at 300 kV onto a 4 k×4 k CCD camera at a
magniﬁcation of 6.1×104, which corresponds to an effective pixel size
of 2.45 Å and a Nyquist sampling limit of 4.9 Å.the viral protein with the heparin are best illustrated by looking outwards from inside
ucent surface is the experimental cryo-EM reconstruction of native, AAV-2 contoured at
(most positive). The potential was calculated from the crystallographic structure (ball-
fference cryo-EM density for the heparin, contoured at a high level (5.7 e.u.) and with its
tively charged surface (blue strip running lower right to upper left) that is formed by the
/487 from subunit A, with Arg448/585 and Arg451/588 from neighboring subunit G which
ding through structure-inspired mutagenesis (Kern et al., 2003; Opie et al., 2003; Xie et
3×9-mer saccharides, modeled in cyan ball-and-stick, surrounding a 3-fold axis (central
ly any one of the conformations averaged in the reconstruction, but only its dimensions.)
lution, contoured at 6.7 e.u. overlaid on the 3 Å crystal structure (Xie et al., 2002). (C) The
ording to atomic properties and to highlight amino acids subject to relevant mutational
ms red and uncharged polar atoms pink. Carbons are colored by mutation phenotype,
. In green are colored residues affecting heparin interactions in any of the studies, darkly
olored in brown, or in gold for those that had at least 10-fold impact upon transduction
st impact (R448/585, R451/588 and R350/487 from), but it extends to include other charged
tains many residues (brown and gold) whose interactions were not detected previously.
ondary receptor binding site proposed to be distinct from the heparin binding site, but
442 J. O'Donnell et al. / Virology 385 (2009) 434–443All 2-D and 3-D processing were performed with the EMAN
software suite (Ludtke et al., 1999). CTFIT was used to assess image
quality. For this, each 4 k×4 k pixel image was sampled with
512×512 pixel sized boxes for power spectrum analysis. Images with
signs of drift or astigmatismwere excluded. Particles within a defocus
range of 0.8 to 3.8 μmwere selected automatically with the AUTOBOX
option in the BOXER program, and manually checked for the presence
of ice crystals, broken particles, or debris.
The reﬁnement of parameters describing the orientation of virus
particles projected in the 2-D EM images (projection alignment)
requires a starting 3-D map. Convergence might have been quicker
had the starting map been simulated from the known crystal
structure. However, to avoid bias, the initial map was built de novo
from the EM images, assuming only that they contained icosahedral
symmetry. In the STARTICOS program of EMAN, the data are searched
for particles with approximate 5-, 3-, or 2-fold symmetry (in
projection), indicating that the symmetry axis in the 3-D particles
was approximately parallel to the projection direction. Particles
exhibiting each of the symmetries were aligned and grouped into
class averages. A 3-D map can then be constructed using the known
angular relations of the icosahedral symmetry axes. Initial reconstruc-
tions were performedwith low pass ﬁltered (20 Å) images and reﬁned
until features of the virus began to emerge. To increase the resolution,
data were corrected for the CTF and the reﬁnement was continued.
Particles were clustered into 179 classes, each corresponding to a
different projection direction within the asymmetric unit. Each cycle
of 3-D particle reconstruction involved 3 rounds of iterative 2-D class
averaging. Individual particle images were excluded if their correla-
tion differed bymore than 0.8 standard errors from themean. 68% and
70% of the total native and complex particles respectively were
included in the ﬁnal reﬁnement. To further remove reference bias and
to be sure that features in the map of the complex were real, the ﬁnal
3-D map was reconstructed using 2-D projection images whose
orientations were reﬁned with reference to the native map. The
resolution was assessed by Fourier Shell Correlation between even
and odd maps with a cutoff of 0.5.
Complex minus native difference maps were calculated using the
“DR DIFF” procedure of the SPIDER program (Frank et al., 1996). In this
procedure the maps are scaled to least-squares minimize their
discrepancy within an optionally masked region. Prior to scaling,
each map was low-pass ﬁltered to the same 8.3 Å resolution as the
complexed particles. For scaling complex to native, the mask was a
spherical shell between 79 and 125 Å, thereby including most of the
capsid protein, but excluding the primary heparin site which began
about 127 Å from the center (and the 3-fold capsid spikes). For
difference map calculation, all maps were brought to a common
scale — that of the low-pass ﬁltered native map, so that a single
estimate of the experimental noise could be used.
The signiﬁcance of features in the maps, relative to noise, was
assessed through analysis of a “mock” difference map, calculated
between the native odd and even image half-data sets. Each data set
was low-pass ﬁltered to 8.3 Å, processed as described above and
scaled to the corresponding full-data native map before calculating
the differences as a measure of error. The histogram of voxels between
79 and 160 Å from the virus center (including all of the capsid protein)
yielded a standard deviation that should correspond to the random
error of difference maps and approximately sqrt(2) times the error of
separate native and complex maps. In the discussion contours are
described in estimated error units (e.u.) rather than standard
deviation or sigma. The latter are often cited in this context, but
usually refer to the variance of the density which is a measure of both
real signal in a map and noise. Note also that the noise is estimated
only from regions containing virus, and is therefore not lowered by
inclusion of solvent regions.
Density was compared to the atomic structure of AAV-2 (RCSB
entry 1LP3) (Xie et al., 2002) using the molecular graphics programCHIMERA (Pettersen et al., 2004), after expanding the icosahedral
symmetry. The electrostatic surface potential was calculated by the
Poisson-Boltzmann equation using the program APBS (Baker et al.,
2001), with the structure of the entire capsid, and assuming a saline
like solvent at 0.15 M salt.
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